Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Active-Controlled, Open-Label, Phase III Trial to Compare the Efficacy and Safety for Treatment of Autologous Chondrocytes Implantation With CartiLife Versus Microfracture for Patients With Knee Chondral Defects

NCT05051332 is registered in ClinicalTrials.gov with Biosolution Co., Ltd. as lead sponsor.

NCT NCT05051332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05051332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Active-Controlled, Open-Label, Phase III Trial to Compare the Efficacy and Safety for Treatment of Autologous Chondrocytes Implantation With CartiLife Versus Microfracture for Patients With Knee Chondral Defects
Lead sponsor
Biosolution Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
March 19, 2020
Completion date
September 30, 2024
Enrollment
104 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

articular cartilage defect, articular cartilage degeneration